Screener
Oruka Therapeutics, Inc. ORKA Conversion Of Series A Nonvoting Convertible Preferred Stock To Common Stock
Conversion Of Series A Nonvoting Convertible Preferred Stock To Common Stock at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept orka:ConversionOfSeriesANonvotingConvertiblePreferredStockToCommonStock.
The source filing: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026.
- Filed
- Mar 12, 2026, 4:03 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001213900-26-026929
| Line item | Series A Convertible Preferred Stock / Shares | Series A Convertible Preferred Stock / Amount | Series A Non-Voting Convertible Preferred Stock / Shares | Series A Non-Voting Convertible Preferred Stock / Amount | Series B Non-Voting Convertible Preferred Stock / Shares | Series B Non-Voting Convertible Preferred Stock / Amount | Common Stock / Shares | Common Stock / Amount | Additional Paid-In / Capital | Accumulated Other Comprehensive / Income (Loss) | Accumulated / Deficit | Total Stockholders’ / Equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization | — | — | — | — | — | — | 1,208,883 | 1 | 4,999 | — | — | 5,000 |
| Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the 2024 PIPE Financing | — | — | 2,439 | 56,097 | — | — | 5,600,000 | 6 | 144,433 | — | — | 144,439 |
| Issuance costs of 2024 PIPE Financing | — | — | — | (3,263) | — | — | — | — | (8,592) | — | — | (8,592) |
| Conversion of Series A non-voting convertible preferred stock to common stock | — | — | (2,439) | (52,834) | — | — | 2,439,000 | 2 | 52,832 | — | — | 52,834 |
| Issuance of common stock under employee stock purchase plan | — | — | — | — | — | — | 2,960 | — | 53 | — | — | 53 |
| Reclassification of the Paruka warrant from liability to equity | — | — | — | — | — | — | — | — | 10,357 | — | — | 10,357 |
| Stock-based compensation expense | — | — | — | — | — | — | — | — | 4,562 | — | — | 4,562 |
| Unrealized losses on marketable securities | — | — | — | — | — | — | — | — | — | (41) | — | (41) |
Item 8. Financial Statements and Supplementary
FAQ
- What is Oruka Therapeutics, Inc.'s conversion of series a nonvoting convertible preferred stock to common stock?
- Oruka Therapeutics, Inc. (ORKA) reported conversion of series a nonvoting convertible preferred stock to common stock of $52.83M in Q4 2024.
- What does conversion of series a nonvoting convertible preferred stock to common stock mean?
- The non-cash value associated with the conversion of preferred equity instruments into common stock. This metric tracks the simplification of the capital structure as preferred shares are retired and replaced by common equity.
Ask your AI about Oruka Therapeutics, Inc.'s conversion of series a nonvoting convertible preferred stock to common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude